Akebia (AKBA) Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve XOANACYL for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease. Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia initiated with a Buy at Jefferies
- Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge
- Akebia Therapeutics Announces Public Offering Pricing
- Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
- Morning Movers: Designer Brands jumps, Accenture falls after quarterly results